Enhanced characterization of contractility in cardiomyocytes during early drug safety assessment

Toxicological Sciences

Volumn 145, Issue 2, 2015, Pages 396-406

  Butler, Larissa ^a   Cros, Caroline ^a,c   Oldman, Karen L ^b   Harmer, Alex R ^a   Pointon, Amy ^a   Pollard, Christopher E ^a   Abi Gerges, Najah ^a  

^a Drug Safety and Metabolism Astra Zeneca   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Cardiac safety; Cardiomyocyte; Drug discovery and development; Hysteresis loop; Inotropy; Pacing rate

Indexed keywords

DIMETHYL SULFOXIDE; FLECAINIDE; INOTROPIC AGENT; ISOPRENALINE; N BENZYL P TOLUENE SULFONAMIDE; OMECAMTIV MECARBIL; SULFONAMIDE; UNCLASSIFIED DRUG; VERAPAMIL; CALCIUM; CARDIOTONIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DOG; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; GEOMETRY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PACING; HEART RATE; HYSTERESIS; IC50; IN VIVO STUDY; NONHUMAN; RISK ASSESSMENT; SARCOMERE LENGTH; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; EXCITATION CONTRACTION COUPLING; HEART CONTRACTION; METABOLISM; SARCOMERE; TIME;

CANIS FAMILIARIS;

ANIMALS; CALCIUM; CARDIAC PACING, ARTIFICIAL; CARDIOTONIC AGENTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATION CONTRACTION COUPLING; FEMALE; HEART RATE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; SARCOMERES; TIME FACTORS;

EID: 84930705169     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfv062     Document Type: Article

References (53)

1. Abi-Gerges, N., Pointon, A., Pullen, G. F., Morton, M. J., Oldman, K. L., Armstrong, D., Valentin, J. P., and Pollard, C. E. (2013). Preservation of cardiomyocytes from the adult heart. J. Mol. Cell. Cardiol. 64, 108-119.
2. Abi-Gerges, N., Valentin, J. P., and Pollard, C. E. (2010). Dog left ventricular midmyocardial myocytes for assessment of drug-induced delayed repolarization: short-term variability and proarrhythmic potential. Br. J. Pharmacol. 159, 77-92.
3. Anonymous, 2000. ICH S7A Safety pharmacology studies for human pharmaceuticals. London, 16 November 2000. CPMP/ICH/539/00. (ICH S7A CPMP/ICH/539/00).
4. Bonow, R. O., Ostrow, H. G., Rosing, D. R., Cannon, R. O., III, Lipson, L. C., Maron, B. J., Kent, K. M., Bacharach, S. L., and Green, M. V. (1983). Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe. Circulation 68, 1062-1073.
5. Borzak, S., Murphy, S., and Marsh, J. D. (1991). Mechanisms of rate staircase in rat ventricular cells. Am. J. Physiol. 260(3 Pt 2), H884-H892.
6. Brixius, K., Hoischen, S., Reuter, H., Lasek, K., and Schwinger, R. H. (2001). Force/shortening-frequency relationship in multicellular muscle strips and single cardiomyocytes of human failing and nonfailing hearts. J. Card. Fail. 7, 335-341.
7. Cambridge, D., and Whiting, M. V. (1986). Evaluation of the QA interval as an index of cardiac contractility in anaesthetised dogs: responses to changes in cardiac loading and heart rate. Cardiovasc. Res. 20, 444-450.
8. 2+ cycling after left ventricular assist device support in the failing human heart. J. Am. Coll. Cardiol. 44, 837-845.
9. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., and Pangalos, M. R. (2014). Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419-431.
10. Coutu, P., and Metzger, J. M. (2002). Optimal range for parvalbumin as relaxing agent in adult cardiac myocytes: gene transfer and mathematical modeling. Biophys. J. 82, 2565-2579.
11. Dulce, R. A., Yiginer, O., Gonzalez, D. R., Goss, G., Feng, N., Zheng, M., and Hare, J. M. (2013). Hydralazine and organic nitrates restore impaired excitation-contraction coupling by reducing calcium leak associated with nitroso-redox imbalance. J. Biol. Chem. 288, 6522-6533.
12. Force, T., Krause, D. S., and Van Etten, R. A. (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332-344.
13. + in rat myocytes showing different force-frequency relationships. Am. J. Physiol. 261(5 Pt 1), C739-C750.
14. Gavaghan, C. L., Arnby, C. H., Blomberg, N., Strandlund, G., and Boyer, S. (2007). Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. J. Comput. Aided Mol. Des. 21, 189-206.
15. Guo, L., Dong, Z., and Guthrie, H. (2009). Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. J. Pharmacol. Toxicol. Methods 60, 130-151.
16. Harmer, A. R., Abi-Gerges, N., Morton, M. J., Pullen, G. F., Valentin, J. P., and Pollard, C. E. (2012). Validation of an in vitro contractility assay using canine ventricular myocytes. Toxicol. Appl. Pharmacol. 260, 162-172.
17. Hasselgren, C., Muthas, D., Ahlberg, E., Andersson, S., Carlsson, L., Noeske, T., Stå lring, J., and Boyer, S. (2013). Chemoinformatics and beyond. In Chemoinformatics for Drug Discovery (J. Bajorath, Ed.). John Wiley & Sons, Inc, Hoboken, NJ.
18. Hayakawa, T., Kunihiro, T., Ando, T., Kobayashi, S., Matsui, E., Yada, H., Kanda, Y., Kurokawa, J., and Furukawa, T. (2014). Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: correlation and complementarity with extracellular electrophysiology. J. Mol. Cell. Cardiol. 77, 178-191.
19. Himmel, H. M. (2013). Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes:effects of reference compounds. J. Pharmacol. Toxicol Methods 68, 97-111.
20. Huebsch, N., Loskill, P., Mandegar, M. A., Marks, N. C., Sheehan, A. S., Ma, Z., Mathur, A. A., Nguyen, T. N., Yoo, J. C., and Judge, L. M., et al. (2015). Automated video-based analysis of contractility and calcium flux in human iPS-derived cardiomyocytes cultured over different spatial scales. Tissue Eng. Part C Methods 21, 467-479.
21. Johnson, D. M., Hussein, L., Spätjens, R. L., Valentin, J. P., Volders, P. G., and Abi-Gerges, N. (2011). Measurement of action potential generation in isolated canine left ventricular midmyocardial myocytes. Curr. Protoc. Pharmacol. Chapter 10, Unit 10.14, 1-23.
22. Joulin, O., Marechaux, S., Hassoun, S., Montaigne, D., Lancel, S., and Neviere, R. (2009). Cardiac force-frequency relationship and frequency-dependent acceleration of relaxation are impaired in LPS-treated rats. Crit. Care. 13, R14.
23. Klumpp, A., Trautmann, T., Markert, M., and Guth, B. (2006). Optimizing the experimental environment for dog telemetry studies. J. Pharmacol. Toxicol. Methods 54, 141-149.
24. Kola, I., and Landis, J. (2004). Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968.
25. 2+ signalling underlying the forcefrequency response in rat ventricularmyocytes: a coupled electromechanicalmodeling study. Theor. Biol.MedModel. 10, 54.
26. Kushnir, A., Shan, J., Betzenhauser, M. J., Reiken, S., and Marks, A. R. (2010). Role of CaMKIIdelta phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. Proc. Natl. Acad. Sci. U. S. A. 107, 10274-10279.
27. Lakatta, E. G. (1993). Cardiovascular regulatory mechanisms in advanced age. Physiol. Rev. 73, 413-467.
28. Lim, C. C., Apstein, C. S., Colucci, W. S., and Liao, R. (2000). Impaired cell shortening and relengthening with increased pacing frequency are intrinsic to the senescent mouse cardiomyocyte. J. Mol. Cell. Cardiol. 32, 2075-2082.
29. Lim, C. C., Liao, R., Varma, N., and Apstein, C. S. (1999). Impaired lusitropy-frequency in the aging mouse: role of Ca(2+)-handling proteins and effects of isoproterenol. Am. J. Physiol. 277(5 Pt 2), H2083-H2090.
30. Markert, M., Klumpp, A., Trautmann, T., Mayer, K., Stubhan, M., and Guth, B. (2007). The value added by measuring myocardial contractility 'in vivo' in safety pharmacological profiling of drug candidates. J. Pharmacol. Toxicol. Methods. 56, 203-211.
31. Marks, L., Borland, S., Philp, K., Ewart, L., Lainée, P., Skinner, M., Kirk, S., and Valentin, J. P. (2012). The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds. Toxicol. Appl. Pharmacol. 263, 171-183.
32. Mellor, H. R., Bell, A. R., Valentin, J. P., and Roberts, R. R. (2011). Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 120, 14-32.
33. Meyer, M., Bluhm,W. F., He, H., Post, S. R., Giordano, F. J., Lew, W. Y., and Dillmann, W. H. (1999). Phospholamban-to-SERCA2 ratio controls the force-frequency relationship. Am. J. Physiol. 276(3 Pt 2), H779-H785.
34. Munos, B. (2009). Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715.
35. 2+ and contraction in single cardiomyocytes. Am. J. Physiol. 259(1 Pt 2), H230-H242.
36. Peters, M. F., Lamore, S. D., Guo, L., Scott, C. W., and Kolaja, K. L. (2015). Human Stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line. Cardiovasc. Toxicol. 15(2), 127-139.
37. Piscione, F., Jaski, B. E., Wenting, G. J., and Serruys, P. W. (1987). Effect of a single oral dose of milrinone on left ventricular diastolic performance in the failing human heart. J. Am. Coll. Cardiol. 10, 1294-1302.
38. Pohlmann, L., Kröger, I., Vignier, N., Schlossarek, S., Krämer, E., Coirault, C., Sultan, K. R., El-Armouche, A., Winegrad, S., and Eschenhagen, T., et al. (2007). Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ. Res. 101, 928-938.
39. Pointon, A., Harmer, A. R., Dale, I. L., Abi-Gerges, N., Bowes, J., Pollard, C., and Garside, H. (2014). Assessment of cardiomyocyte contraction in human-induced pluripotent stem cellderived cardiomyocytes. Toxicol. Sci. 144(2), 227-237.
40. Pollard, C. E., Abi-Gerges, N., Bridgland-Taylor, M. H., Easter, A., Hammond, T. G., and Valentin, J. P. (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br. J. Pharmacol. 159, 12-21.
41. Redfern, W. S., Carlsson, L., Davis, A., Lynch, W., MacKenzie, I., Palethorpe, S., Siegl, P. K., Strang, I., Sullivan, A. T., and Wallis, R., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45.
42. Ren, J., and Wold, L. E. (2001). Measurement of cardiac mechanical function in isolated ventricular myocytes from rats and mice by computerized video-based imaging. Biol. Proced. Online 3, 43-53.
43. Rota, M., Boni, A., Urbanek, K., Padin-Iruegas, M. E., Kajstura, T. J., Fiore, G., Kubo, H., Sonnenblick, E. H., Musso, E., and Houser, S. R., et al. (2005). Nuclear targeting of Akt enhances ventricular function and myocyte contractility. Circ. Res. 97, 1332-1341.
44. Schmidt, U., del Monte, F., Miyamoto, M. I., Matsui, T., Gwathmey, J. K., Rosenzweig, A., and Hajjar, R. J. (2000). Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circulation 101, 790-796.
45. Schulz, M., and Schmoldt, A. (2003). Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58, 447-474.
46. Scott, C. W., Peters, M. F., and Dragan, Y. P. (2013). Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicol. Lett. 219, 49-58.
47. Scott, C. W., Zhang, X., Abi-Gerges, N., Lamore, S. D., Abassi, Y. A., and Peters, M. F. (2014). An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. Toxicol Sci. 142, 331-338.
48. Sirenko, O., Crittenden, C., Callamaras, N., Hesley, J., Chen, Y. W., Funes, C., Rusyn, I., Anson, B., and Cromwell, E. F. (2013a). Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. J. Biomol. Screen. 18, 39-53.
49. Sirenko, O., Cromwell, E. F., Crittenden, C., Wignall, J. A., Wright, F. A., and Rusyn, I. (2013b). Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity. Toxicol. Appl. Pharmacol. 273, 500-507.
50. Soppa, G.K., Lee, J., Stagg, M. A., Felkin, L. E., Barton, P. J., Siedlecka, U., Youssef, S., Yacoub, M. H., and Terracciano, C. M. (2008). Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. Cardiovasc. Res. 77, 695-706.
51. Udelson, J. E., Cannon, R. O., III, Bacharach, S. L., Rumble, T. F., and Bonow, R. O. (1989). Beta-adrenergic stimulation with isoproterenol enhances left ventricular diastolic performance in hypertrophic cardiomyopathy despite potentiation of myocardial ischemia. Comparison to rapid atrial pacing. Circulation 79, 371-382.
52. Timolati, F., Anliker, T., Groppalli, V., Perriard, J. C., Eppenberger, H. M., Suter, T. M., and Zuppinger, C. (2009). The role of cell death and myofibrillar damage in contractile dysfunction of long-term cultured adult cardiomyocytes exposed to doxorubicin. Cytotechnology 61, 25-36.
53. Wang, Y. G., Benedict, W. J., Hüser, J., Samarel, A. M., Blatter, L. A., and Lipsius, S. L. (2001). Brief rapid pacing depresses contractile function via Ca(2+)/PKC-dependent signaling in cat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 280, H90-H98.